RA biologics comparison
RheumatologyCompare biologic and targeted synthetic DMARDs for rheumatoid arthritis. After failing conventional DMARDs, patients have multiple biologic options. Choice depends on mechanism, route, insurance coverage, and individual risk factors.
Select any two to compare side by side
All products in this comparison
| Product | Manufacturer | Route | Frequency | Key difference |
|---|---|---|---|---|
| Humira | AbbVie | SC injection | Every 2 weeks | Most prescribed biologic for RA; extensive data; biosimilars available |
| Enbrel | Amgen | SC injection | Weekly | TNF receptor fusion protein; different mechanism than monoclonal antibody TNFi |
| Orencia | BMS | IV infusion or SC injection | Monthly (IV) or weekly (SC) | T-cell costimulation modulator; different mechanism than TNF inhibitors |
| Kevzara | Sanofi/Regeneron | SC injection | Every 2 weeks | IL-6 receptor antagonist; effective as monotherapy (without methotrexate) |
| Rinvoq | AbbVie | Oral (tablet) | Daily | JAK inhibitor; oral; black-box warning limits to post-biologic failure |
| Xeljanz | Pfizer | Oral (tablet) | Twice daily or once daily (XR) | First oral JAK inhibitor for RA; black-box warning |
| Cimzia | UCB | SC injection | Every 2–4 weeks | PEGylated TNFi; no active placental transfer (preferred in pregnancy) |
| Remicade | Janssen | IV infusion | Every 4–8 weeks | IV TNFi; biosimilars widely available and often preferred by payers |
Related guides
Denied one of these medications?
Ellen can decode your denial letter, identify why you were denied, and generate a personalized appeal, free for patients.